Introduction
The current 5-year event-free survival rate is nearly 80% for children with acute lymphoblastic leukemia (ALL) (Pui et al., 2004) . However, T-cell ALL (T-ALL), a subtype of ALL accounting for 10-15% of pediatric ALL cases, is associated with a poorer prognosis and requires intensified therapy to obtain a 5-year relapsefree survival rate of 60-75% (Pui and Evans, 1998; Schrappe et al., 2000; Silverman et al., 2001 ). Furthermore, patients with T-ALL who experience a bone marrow relapse have a dismal outcome. In a study published by Henze et al. (1991) no patient with T-cell ALL who suffered an early bone marrow relapse was alive 15 months later. Further understanding of the development of T-ALL can have significant clinical impact through improving patient outcomes.
Tyrosine kinases (TK) have been shown to play a role in leukemogenesis. These include ABL, PDGFRa, FGFR1 in chronic myeloid leukemia (CML), and FLT3, NTRK3, c-FMS, c-Kit, JAK2, ARG, and Axl in acute myeloid leukemia (AML) (Krause and Van Etten, 2005) . In T-ALL/lymphoma, translocations that result in aberrant activation of TKs have been identified, including fusion of the TK ABL to nucleoporin 214 in 5% of T-ALL, and the fusion of FGFR3 receptor tyrosine kinase (RTK) to ETV6/TEL in T-cell lymphoma (Graux et al., 2004; Krause and Van Etten, 2005) .
We have previously cloned a novel proto-oncogene, Mer (MerTK, Nyk, , from a cDNA lymphoblastoid library (Graham et al., 1994 (Graham et al., , 1995 . Mer is a member of an RTK family that includes Axl and Tyro-3. This Mer/Axl/Tyro-3 family is stimulated by a common ligand Gas6 (Chen et al., 1997) . After binding to the ligand Gas6, Mer activates downstream antiapoptotic pathways, possibly contributing to cancer development. Mer activation is transforming in vitro (Ling and Kung, 1995; Georgescu et al., 1999) , and c-eyk, the putative avian ortholog of Mer, is a protooncogene known to cause fibrosarcomas, endotheliomas, and visceral lymphomatosis in chickens (Jia et al., 1992; Jia and Hanafusa, 1994) . Mer overexpression has been demonstrated in many human cancers, including mantle cell lymphoma (Ek et al., 2002) , E2A-PBX1 B-cell leukemia (Yeoh et al., 2002) , alveolar rhabdomyosarcoma (Khan et al., 1999) , gastric cancer (Wu et al., 2002) , and pituitary adenomas (Evans et al., 2001) .
Although not expressed in normal lymphocytes or thymocytes, we have previously demonstrated that Mer is ectopically expressed in T-ALL cell lines (Graham et al., 1994) and patient samples (Graham et al., 2006) . This abnormal Mer expression raises the possibility that Mer may be involved in the pathogenesis of T-ALL and lymphoma. To test this hypothesis, we constructed a transgenic mouse model (Mer Tg ) that aberrantly expresses Mer in lymphocytes and thymocytes. We found that Mer Tg mice developed T-cell ALL and lymphomas at a significantly higher rate compared to the wild type, indicating a contributing role of Mer in T-cell leukemogenesis. Additionally, stimulation of Mer results in activation of anti-apoptotic pathways, and Mer Tg lymphocytes exhibit decreased sensitivity to dexamethasone-induced cell death. This suggests a mechanism by which aberrant Mer expression may contribute to leukemogenesis and resistance to treatment with standard chemotherapies.
Results

Construction of Mer transgenic mice
Previous work in our laboratory demonstrated that Mer is atypically expressed in lymphoblasts in greater than 50% of patients with T-ALL (Graham et al., 2006) . In order to investigate the effect of aberrant Mer expression on leukemogenesis, we generated a Mer transgenic mouse with the Vav promoter ( Figure 1a) driving expression of the transgene in all nucleated cells of the hematopoietic tissues, including both lymphocytes and thymocytes . A total of nine founder mice were identified as having the Vav-Mer construct by a PCR screening assay (Figure 1b) . Germ-line transmission allowed the propagation of five lines initially. The insertion site of the Vav-Mer transgene in two founders, founder 2 (Mer Tg F2) and founder 11 (Mer Tg F11), was evaluated by fluorescence in situ hybridization (FISH) (Figure 1c ). The insertion of the Vav-Mer transgene on different chromosomes in these two founders eliminated the concern that an observed phenotype resulted from a specific insertional mutation.
Insertion of the Mer transgene results in expression of functional Mer protein in lymphocytes and thymocytes
Mer is known to be expressed by many hematopoietic cell lineages, including macrophages, dendritic cells, NK cells, and NKT cells (Behrens et al., 2003) . We examined Mer expression by flow cytometry in these cell lineages and found no difference in Mer surface protein levels between the Mer Tg and wild type (data not shown). Mer is not normally found on wild-type lymphocytes or thymocytes. We demonstrated that Mer was absent in the wild-type lymphocyte and thymocyte but was ectopically expressed in the Mer Tg F2 cells (Figure 2a) , and similarly in the Mer Tg F11 cells (data not shown). Using CD4/CD8 co-sorting with Mer, we confirmed aberrant Mer expression in lymphocytes obtained from peripheral lymph nodes (Figure 2a ) as well as lymphocytes from the spleen (data not shown) of Mer Tg mice. Additionally, we verified that Mer was present in all thymocyte developmental subsets (CD4ÀCD8À, CD4 þ CD8 þ , CD4 þ CD8À, CD4ÀCD8 þ ), and that there was no alteration in subset population distribution (data not shown). Western-blot analysis also demonstrated Mer protein expression (Figure 2b ) in Mer Tg thymocytes and lymphocytes. The cell line HEK293 (293), a human embryonic kidney cell (Graham et al., 1977) , was used as a negative control for mouse Mer expression, as the anti-mouse Mer antibody used is species specific and will not detect human Mer. HEK293 cells expressing full-length mouse Mer were used as positive controls. In the HEK293 cells transfected with mouse Mer cDNA, two different Mer protein products, at approximately 200 and 175 kDa, were detected (Graham et al., 2006) .
To demonstrate that the Mer protein expressed in the transgenic mouse was functional and could undergo autophosphorylation when activated, thymocytes from a Mer Tg F2 and a wild-type mouse were stimulated with 200 nM Gas6. Mer Tg thymocytes treated with Gas6 demonstrated Mer phosphorylation, indicating that the transgenic Mer protein was functional (Figure 2c ).
Mer Tg mice develop clonal T-cell leukemia/lymphoma at a significantly higher rate compared to wild type Wild-type and Mer Tg mice were monitored at regular intervals for signs and symptoms of illness. During the interval of 6-12 months of age, there were no signs of illness. Flow cytometry and histopathological analysis of blood and tissues from both the transgenic and wildtype mice under 12 months of age did not reveal evidence of cancer. Peripheral white blood cell differentials of wild-type and Mer Tg non-malignant mice were similar. Additionally, T-cell subset analysis of thymus and lymph node tissue of Mer Tg mice was similar to the wild-type mice (data not shown). However, as the mice reached 12-24 months of age, symptoms including weight loss, decreased activity, lethargy, hepatosplenomegaly, and adenopathy developed (Figure 3a and b). Histopathological analysis of enlarged mesenteric and mediastinal lymph nodes of the transgenic mice revealed sheets of lymphoblasts (Figure 3c ), whereas evaluation of the peripheral blood smear showed the presence of circulating lymphoblasts (data not shown). Coulter analysis of the peripheral blood revealed that malignant Mer Tg mice developed an expansion to 18-36% of a midrange population of white blood cells compared to only 5-11% in the wild type (data not shown). All mice not showing signs of illness were killed at 24 months and evaluated for malignancy. The tumor-free survival of the Mer Tg mice was significantly shorter in both the Mer Tg F2 and Mer Tg F11 lineages compared to the wild type ( Figure 4 ). The wild-type mice had a tumor rate of 12% at 24 months, similar to published data of leukemia/lymphoma incidence on a C57Bl/6 background (Naf et al., 2002) . However, the Mer Tg F2 and Mer Tg F11 leukemia/lymphoma rates were significantly higher at 58% (P ¼ 0.003) and 55% (P ¼ 0.01), respectively.
Lymphomas from 19 transgenic mice were analysed by flow cytometry for expression of T-cell marker THY1.2 and the B-cell marker CD45-B220. Fourteen T-cell lymphomas stained positive for PE-THY1.2. Three biphenotypic lymphomas stained for both PE-THY1.2 and PE-CY7-B220, while two bilineage lymphomas exhibited two distinct blast populations, one was positive for PE-THY1.2, and the other for PE-CY7-B220 (Figure 3d and data not shown). The lymphoblasts of the transgenic mice also expressed Mer (Figure 3d and data not shown). We further analysed the T-cell lymphomas with the antibodies against CD3, CD4, and CD8 to assess the T-cell developmental stage of the lymphoblasts. All three stages of thymocyte development were present in the tested T-cell lymphomas (Ferrando et al., 2002) . There were one immature (CD3
lymphomas. Flow cytometry analysis further confirmed that the lymphomas were clonal, with the T-cell lymphoblasts expressing a large percentage of a single Vb rearrangement. Using a panel of 17 antibodies that recognize proteins resulting from different Vb rearrangements, 0-15% of lymphocytes isolated from wild-type mice expressed each of the Vb markers (Figure 3e and data not shown). In contrast, clonal expansion of specific T-cell receptors was noted on lymphoblasts from the Mer Tg . In Figure 3e , 51.4% of the lymphocytes isolated Stimulation of Mer Tg lymphocytes with Gas6 leads to activation of anti-apoptotic signaling Alterations in RTK signaling leading to activation of downstream anti-apoptotic and proliferative pathways is a well-described mechanism in cancer pathogenesis (Reed, 1999; Blume-Jensen and Hunter, 2001) . We evaluated downstream signaling of Mer in Mer Tg lymphocytes and found that activation of Mer through the addition of Gas6 led to the phosphorylation and activation of anti-apoptotic pathways, including Akt and ERK1/2. The activation of PI3K/Akt and ERK1/2 was seen only in the Mer Tg lymphocytes and not in cells derived from wild-type or Mer KO mice. This activation of anti-apoptotic pathways downstream of Mer stimulation is consistent with previous findings (Guttridge et al., 2002) .
Expression of Mer protein provides a survival advantage
The activation of downstream anti-apoptotic pathways in Mer Tg lymphocytes suggests a functional role for Mer. Dexamethasone was selected as the apoptotic inducer for these experiments as it is a critical component of current leukemia/lymphoma therapy. In order to determine whether Mer can promote survival, we evaluated cytotoxicity in Mer Tg lymphocytes from preleukemic mice in response to dexamethasone treatment. The range of dexamethasone concentrations was 0.25-25 nM, which are physiologically relevant doses in humans. At all dexamethasone concentrations tested, we found that Mer Tg lymphocytes had a statistically significant survival advantage over the wild-type Figure 4 Lymphoma-free survival in Mer Tg mice is significantly lower compared to wild-type. Kaplan-Meier analysis comparing tumor-free survival in Mer Tg F2 and Mer Tg F11 to wild-type (WT). Analysis illustrates a statistically significant reduction in tumor-free survival with the Mer Tg F2 rate of 42% (P ¼ 0.003) and Mer Tg F11 rate of 45% (P ¼ 0.01), compared to the WT rate of 88%.
cells. This anti-apoptotic survival difference is consistent with other investigator's findings in experiments with other apoptotic stimuli (Georgescu et al., 1999; Guttridge et al., 2002) . The survival response noted in Mer Tg lymphocytes in response to dexamethasone suggests a mechanism through which Mer activation may contribute to oncogenesis and is a potential mechanism for chemotherapy resistance.
Discussion
We developed a transgenic mouse model, Mer Tg , which has ectopic expression of Mer in lymphocytes and thymocytes. This mouse model mimics the aberrant expression of Mer found in a subset of T-ALL patient samples (Graham et al., 2006) . The mouse Mer Tg model and experiments described here demonstrate that aberrant Mer expression promotes the development of T-cell predominant leukemia/lymphoma.
Receptor tyrosine kinases aid in the regulation of most cellular processes including cell cycle, migration, metabolism, survival, proliferation, and differentiation (Schlessinger, 2000) . Malignant cells must manifest several acquired abnormalities in these cell processes in order to transform and proliferate. One main mechanism is evasion of apoptosis (Reed, 1999; Hanahan and Weinberg, 2000) . Through anti-apoptotic activity, the pre-leukemic cell is able to prolong its lifespan while accumulating additional advantageous mutations, transform, and potentially become more resistant to treatment (Reed, 1999) . Two anti-apoptotic pathways that are regulated though RTK signaling are PI3K/Akt and MAPK/ERK1/2 (Hanahan and Weinberg, 2000; BlumeJensen and Hunter, 2001 ). Activation of PI3K/Akt and MAPK/ERK1/2 has previously been associated with human disease and specifically leukemia (Vivanco and Sawyers, 2002; Anderson and Jackson, 2003; Grandage et al., 2005) .
We have shown that stimulation of the Mer Tg protein with its specific ligand Gas6 in transgenic lymphocytes led to phosphorylation and activation of Akt and ERK1/2 ( Figure 5 ). This activation of anti-apoptotic pathways through Mer RTK signaling likely contributes to the evasion of normal cellular processes and thus leukemogenesis in our Mer Tg mouse model. Guttridge et al. (2002) have shown that transfection of 32D cells with a Mer/EGFR chimera caused anti-apoptotic signaling through Akt and ERK1/2 and eventual cellular transformation. Chen et al. (1997) have described interactions of the ligand Gas6 and the Mer/Axl/ Tyro-3 family of RTKs as being transforming in vitro (Chen et al., 1997) and Dirks et al. (1999) have found these interactions to be associated with leukemia and lymphoma cell line proliferation. The Gas6-mediated stimulation of Mer that we observed in vitro should also occur with the Mer Tg lymphocytes in the bone marrow and peripheral blood in vivo, as Gas6 is produced by bone marrow stromal cells (Dormady et al., 2000) and is found in the plasma (Borgel et al., 2006) .
We illustrate a functional survival advantage offered by Mer in preleukemic lymphocytes in primary culture. Glucocorticoids, including dexamethasone, are a mainstay of leukemia and lymphoma therapy. Poor response to glucocorticoid treatment is associated with high risk of relapse and requires augmented therapy to attain standard cure rates. Mer Tg lymphocytes had a statistically significant increased survival advantage over the wild-type lymphocytes in response to treatment with dexamethasone ( Figure 6 ). Similar anti-apoptotic survival effects were observed with Mer stimulation in murine leukemia 32D cells and Ba/F3 pro-B lymphocytes (Georgescu et al., 1999; Guttridge et al., 2002) .
The latency of the development of leukemia/lymphoma in our Mer Tg model suggests that the activation of additional pathways may be involved, and that the Mer proto-oncogene most likely requires cooperativity with other oncogenic events to develop malignancy. Cancer is a multi-step process and activation of a single oncogene rarely leads to tumorigenesis, with the possible exception of the development of acute leukemia in BCR-ABL transgenic mice (Heisterkamp et al., 1990) . In most mouse models of leukemia/lymphoma, there is lateonset leukemia and lymphoma owing to cooperativity of multiple oncogenes. Specifically, transgenic mice expressing the c-Myc oncogene under the control of the Igh enhancer Em do not develop B-cell lymphoma/leukemia until the end of the first year of life (Harris et al., 1988; Adams et al., 1999) . However, the development of B-cell lymphoma is markedly accelerated when Myc is co-expressed with the anti-apoptotic oncogene Bcl-2 (Strasser et al., 1990) . Also, disruption of the ARFMdm2-p53 tumor suppressor pathway has been shown to accelerate lymphomagenesis in Em-Myc mice (Eischen et al., 1999) . Furthermore, inactivation of the Bcl-2 antagonist Bim has been shown to accelerate Myc-induced development of B lymphomas/leukemia (Egle et al., 2004) . Similar oncogene cooperativity in the development of T-cell leukemia/lymphoma has been demonstrated in mice lacking one allele of Smad3 and carrying a homozygous deletion of p27 Kip1 (Wolfraim et al., 2004) .
Tyrosine kinases play an important role in cell cycle regulation, and have been implicated in cancer pathophysiology for decades. The recent introduction of TK inhibitors into cancer therapeutic regimens has provided unique treatment options with less toxic side effects than traditional chemotherapy (Krause and Van Etten, 2005; Tibes et al., 2005) . Imatinib mesylate inhibits the constitutively active tyrosine kinase fusion product arising from the BCR-ABL oncogene, causing specific inhibition of proliferating myeloid cells containing the potent oncogenic BCR-ABL protein, and inducing remission in many patients with CML (Druker et al., 1996; Savage and Antman, 2002) . Furthermore, the effects of inhibition on other cooperative RTKs, such as FLT3 and c-Kit, with small molecule TK inhibitors are being tested clinically in patients with AML (Gilliland and Griffin, 2002) , and gastrointestinal stromal tumors (Sattler and Salgia, 2004) . The use of monoclonal antibodies, such as trastuzumab to target the EGFR family in breast cancer and osteosarcoma, are also being developed to target RTK activation and signaling. In a similar manner, the ectopic expression of Mer RTK in human T-cell lymphoblasts and the role of Mer in the development of lymphoblastic leukemia/lymphoma as demonstrated in the Mer Tg mice makes this tyrosine kinase an attractive candidate for biologically targeted therapy in ALL and possibly other Mer-positive cancers.
Materials and methods
Animals
Wild-type (C57Bl/6) mice were purchased from Jackson Laboratories. Mer KO mice were kindly provided by Drs Glenn Matsushima and HS Earp (University of North Carolina, Chapel Hill, NC). The care of animals and experimental procedures were in accordance with the guidelines of the University of Colorado Center for Comparative Medicine.
Generation of Mer transgenic mice
The full-length Mer mouse cDNA sequence was subcloned into the HS21/45 Vav hematopoietic vector (kindly provided by Dr Jerry Adams, Victoria, Australia) between the Sfi1 and Not1 sites Ogilvy et al., 1999) . The pIC19H backbone (2.7 kb) was removed from the vector by HindIII digestion and gel purification (Qiagen Sciences, Valencia, CA, USA). Purified constructs were microinjected into single cell fertilized C57Bl/6 Â SJL embryos that were subsequently transferred into the oviduct of a pseudopregnant mouse at the University of Cincinnati Transgenic Mouse Core. Founder mice (9) were identified by PCR assay for the VavMer transgene using genomic DNA isolated from tail clippings. Polymerase chain reaction with reverse transcription (RT-PCR) was performed at an annealing temperature of 551C using two forward primers, Vav AF (5 0 -AAGCTGAGA TCTGGCCCGTAC-3 0 ) and Vav BF (5 0 -CAAAGAACTG CTCCTCAGTG-3 0 ) found within the Vav promoter and the reverse primer Mer 110R (5 0 -GGAGTGAGGAGCAGAGA ATGG-3 0 ) in the mouse Mer extracellular domain. Two founder lines, Mer Tg F2 and Mer Tg F11, with germ-line transmission were selected for backcrossing with C57Bl/6 wild-type mice. Mer Tg lines were backcrossed a minimum of three times before phenotype analysis.
Fluorescence in situ hybridization Kidneys were harvested from C57Bl/6 wild type, Mer Tg F2 and Mer Tg F11 mice and cultured using standard cytogenetic techniques to obtain interphase cells and metaphase spreads for analysis. Vav-Mer DNA used for DNA microinjection to create transgenic mouse founder lines was directly labeled with Spectrum Orange (Vysis) using the Vysis Nick Translation Kit. FISH analyses were performed using standard techniques. A minimum of 100 interphase cells and 5 metaphase spreads were analysed from each mouse line to determine copy number and site of insertion of the transgene.
Flow cytometry
Single-cell suspensions were made from thymocytes and lymphocytes isolated from wild-type and transgenic mice by passing tissues through a 100 mm cell strainer. A total of 5 Â 10 5 cells were washed in phosphate-buffered saline (PBS) containing 2% fetal calf serum and then stained in 50 ml 13, 14, 17; BD Biosciences, San Diego, CA, USA). Fluorescence was detected and analysed using a FC500 flow cytometer (Beckman Coulter) with CXP data analysis software.
Mer transfection in HEK293 cells HEK293 cells were obtained from the American Type Culture Collection (ATCC) and were maintained per ATCC culture guidelines. HEK293 cells were transfected using lipofectamine (Invitrogen, Carlsbad, CA, USA) to introduce full-length mouse Mer cDNA subcloned into pCDNA3 (Invitrogen).
Mer activation with Gas6
Peripheral node lymphocytes and thymocytes were made into single-cell suspension. Cells were plated at equal concentrations in the absence of serum for 2-3 h before treatment with 200 nM Gas6 (R&D Systems) for 10 min. Cells were then washed with PBS pH 7.4, centrifuged, and prepared for immunoblotting.
Immunoblotting
Lysates from cell lines and mouse tissues were prepared using a lysis buffer containing 50 mM HEPES pH 7.5, 150 mM NaCl, 10 mM EDTA, 10% glycerol and 1% Triton X-100 and supplemented with a protease inhibitor cocktail (Roche Molecular Biochemicals, Indianapolis, IN, USA) and phosphatase inhibitors of 200 mM Na 3 VO 4 and 10 mM Na 2 MoO 4 . For immunoprecipitation experiments, lysates were incubated with anti-mMer antibody (R&D Systems) for 30 min on ice, and rocked for an additional hour at 41C with protein G sepharose beads. Immunoprecipitates were collected by centrifugation and washed three times in lysis buffer. Proteins were resolved electrophoretically in a denaturing 8% SDS-PAGE gel and transferred by electroblotting to nitrocellulose membranes. Membranes were blocked in TBST with 5% milk for 1 h and then probed with the corresponding antibodies, with actin or JNK probed as a protein loading control. Actin was detected with a goat polyclonal antibody while JNK was evaluated by a rabbit polyclonal antibody (Santa Cruz Biotechnology, Santa Cruz, CA, USA); human Mer protein was evaluated by A311 Mer mouse monoclonal antibody (Caveo Therapeutics, Aurora, CO, USA); phospho-tyrosine was detected with p-Tyr mouse monoclonal antibody (4G10) (Upstate Cell Signaling Solutions, Lake Placid, NY, USA); mouse Mer was detected with a goat polyclonal antibody (R&D Systems); phospho-Mer was evaluated with a rabbit polyclonal antibody (FabGennix, Frisco, TX, USA); Akt and phospho-Akt (Ser473), and ERK1/2 were detected with their respective rabbit polyclonal antibody, while phospho-ERK1/2 (Thr202/Tyr204) was detected with a mouse monoclonal antibody (Cell Signaling Technologies). Proteins were visualized with an HRP-based enhanced luminol SuperSignal West Pico chemiluminescent system (Pierce Biotechnology, Rockford, IL, USA).
Evaluation of mice for lymphoma C57Bl/6 WT, Mer Tg F2, and Mer Tg F11 mice were evaluated several times a week from 12 to 24 months of age. Mice showing signs of illness, such as decreased activity, weight loss, organomegaly, or palpable tumor, were sacrificed and dissected. Peripheral blood was stained with Wright and Giemsa (Sigma, St Louis, MO, USA). Abnormal lymph nodes and organs were harvested for flow cytometric and histopathological analysis. Samples for histopathology were fixed for at least 24 h in 10% formalin, dehydrated in alcohol, cleared in xylene, infiltrated with paraffin, and sectioned. Tissue sections were deparaffinized in xylene and rehydrated through graded alcohol solutions before staining with hematoxylin and eosin (H&E). Hematoxylin and eosin slides were evaluated in a blinded manner by a clinical hematopathologist from The Children's Hospital, Denver.
Functional assay of apoptosis Lymph nodes were obtained from 8-10 week old female wildtype and Mer Tg littermates. Single cell suspensions were generated in PBS containing 1% fetal bovine serum (FBS) and 100 U/ml DNase I (Sigma-Aldrich, St Louis, MO, USA). Cells were treated with hemolytic Gey's Solution (0.155 M ammonium chloride, 10 mM potassium bicarbonate) for 5 min to lyse red blood cells, washed with 1 ml PBS, and cultured at a density of 5 Â 10 6 cells/ml in RPMI medium containing 10% FBS. Cultures were treated with dexamethasone (SigmaAldrich) at the indicated concentrations for 12.5 h. Samples were then recovered, stained for 20 min with 100 nM Yo-Pro-1 iodide (Invitrogen) and 1.5 mM propidium iodide (Invitrogen) in PBS, and analysed by flow cytometry.
Statistical analyses
Kaplan-Meier survival analysis was performed on all three groups (WT, Mer Tg F2, and Mer Tg F11) of mice. Survival curves among the groups were compared using the log-rank test. The false discovery rate procedure was used to control for multiple paired comparisons of survival (Curran-Everett, 2000) . Data analyses were performed using SAS Version 9.1 (SAS Institute). Statistical analyses of apoptosis assay were performed using GraphPad Prism v4.0 (GraphPad Software Inc.). P-values were calculated using log (% relative survival) for Student's unpaired t-test or dose-response curves fitted by nonlinear regression for extra-sum-of-squares F-test.
